Course Summary

Expiration Date: 02/03/2028

Psychedelic-assisted psychotherapy (PAP) combines psychedelic drugs and psychotherapy, the biological and psychological effects of the drug, and psychiatric intervention. Psychedelic drugs have been divided into four categories that are often regarded as classic psychedelics: LSD, mescaline, dimethyltryptamine (DMT), and psilocybin. PAP has been used to treat major depressive disorder (MDD), post-traumatic stress disorder (PTSD), substance use disorders (SUD),anxiety and depression, and several substance use disorders, e.g., alcohol and tobacco. It has also become an important part of palliative care treatment. While not a new treatment in the United States, research on the therapeutic potential of psychedelics continues to be considered investigative.

Course Format

Homestudy

Course Syllabus

  • Introduction
    • Psychedelic Drug: Definition
  • What Is Psychedelic Assisted Therapy?
    • Psychedelic Drug: Definition
  • Neurotransmitters, Neurotransmitter Receptors, and Psychedelics
    • Serotonin
    • N-methyl-D-aspartateand Glutamate
    • Catecholamines and Monoamine Oxidase
  • The Psychedelic Experience
    • Tryptamines
    • Phenylethylamines
    • Ketamine
    • Other Psychedelics
  • The Process of Psychedelic-Assisted Psychotherapy
    • Preparation
    • PAP Session and Post-treatment
    • PAP Questions and Issues
  • Treatment Indications
    • Major Depressive Disorder and Treatment-Resistant Depression
    • DMT
    • Ketamine
    • LSD
    • Psilocybin
    • Post-Traumatic Stress Disorder
    • PTSD and MDMA
    • Ketamine and PTSD
    • Ayahuasca, DMT, Ibogaine, LSD, Mescaline, Amanita Muscaria, and Salvia divinorum
  • Alcohol Use Disorder
    • Ayahuasca
    • DMT
    • Ibogaine
    • Ketamine
    • LSD
    • MDMA
    • Mescaline
    • Psilocybin
  • Adverse Effects
    • Ayahuasca
    • DMT
    • Ibogaine
    • Ketamine
    • LSD
    • Other Hallucinogen Use Disorder
    • MDMA
    • Mescaline
    • Psilocybin
    • Hallucinogen Persisting Perception Disorder
    • Fatalities and Psychedelics
    • Suicide
  • Drug-Drug Interactions
    • Ayahuasca, DMT, LSD, Mescaline, Psilocybin
    • Ketamine
    • Ibogaine, Amantia muscaria, Salvia divinorum
  • PAP: Unresolved Issues in the Literature
    • Blinding
    • Study Design and Adverse Effects
    • PAP Process
  • Summary

Author

Dana Bartlett, RN, BSN, MSN, MA, CSPI

Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 27 years as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, textbook chapters, and more than 100 online CE articles, and done editing and reviewing for publishers such as Elsevier, Lippincott, and Thieme. He has written widely on the subject of toxicology and was a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center. He lives in Wappingers Falls, NY.